<DOC>
	<DOCNO>NCT01355484</DOCNO>
	<brief_summary>The purpose study determine investigational drug GTx-024 help subject non-small cell lung cancer increase physical function maintain gain muscle , also call `` lean body mass '' .</brief_summary>
	<brief_title>Phase III Study Effect GTx-024 Muscle Wasting Patients With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , multicenter , multinational efficacy safety study subject non small cell lung cancer ( NSCLC ) . Subjects evenly randomize placebo GTx-024 prior initiation first line chemotherapy . The primary efficacy analysis base total lean body mass physical function .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>give voluntary , sign informed consent accordance institutional policy nonobese define body mass index ( BMI ) &lt; = 32 weight &lt; 300 pound ( &lt; 136kg ) diagnose Stage III IV NSCLC prior first line chemotherapy plan first line chemotherapy regimen platinum plus paclitaxel platinum plus docetaxel surgery part cancer treatment , screen study conduct least 4 week ( 28 day ) surgery life expectancy &gt; 6 month ECOG score &lt; or=1 Serum creatinine &lt; or=2.0 mg/dL MALES age &gt; or= 30 year FEMALES age &gt; or=30 year clinically confirm postmenopausal.Subjects must undergo onset spontaneous surgical menopause prior start study . Spontaneous menopause define natural cessation ovarian function indicate amenorrheic least 12 month . If subject amenorrheic &gt; or=6 month &lt; 12 month must serum FSH concentration &gt; or=50 mIU/mL estradiol concentration &lt; or=25 pg/mL . Surgical menopause define bilateral oophorectomy . MALES subject must agree use double barrier method contraception study 3 month study completion . This may include follow : condom + spermicide condom + oral hormonal contraception MALES serum PSA &lt; or=4.0 ng/mL negative prostate biopsy ( prostate cancer ) within 6 month evaluation Have , judgment investigator , clinically significant concurrent illness psychological , familial , sociological , geographical concomitant condition would permit adequate followup compliance study protocol Have ALT/SGOT AST/SGPT 1.5 time upper limit normal ( ULN ) without evidence liver metastases 5 time ULN subject evidence liver metastasis Have alkaline phosphatase great 3 time ULN and/or total bilirubin level 2 mg/dL baseline Have biologic agent kinase inhibitor part first line chemotherapy regimen include , limited bevacizumab ( Avastin ) , gefitinib ( Nexavar ) erlotinib ( Tarceva ) Cardiovascular : uncontrolled hypertension , congestive heart failure angina Pulmonary : Stage 4 chronic obstructive pulmonary disease ( COPD ) positive screen Hepatitis B consist HBsAg ( Hepatitis B Surface Antigen ) , unless subject diagnose &gt; 10 year prior enrollment evidence active liver disease positive screen antiHCV ( Hepatitis C Antibody ) , hepatitis A antibody IgM , HIV currently take testosterone , oxandrolone ( Oxandrin ) , testosteronelike agent ( dehydroepiandrosterone ( DHEA ) , androstenedione , androgenic compound , include herbal ) , antiandrogens ; previous therapy testosterone testosteronelike agent acceptable 30 day washout ( previous testosterone therapy long term depot within past 6 month , site contact medical monitor study determine appropriate washout period ) currently take megestrol acetate ( Megace ) , dronabinol ( Marinol ) , medical marijuana ( medical cannabis ) prescription medication intend increase appetite treat unintentional weight loss baseline stair climb time &gt; or=30 second ( mean two stair climb ) Have active cancer , NSCLC , nonmelanoma carcinoma skin , within previous two year</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>